What is MEDS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.01B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MEDS?

P/E (TTM) is n/a and 52-week range is $0.82 to $12.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MEDS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MEDS?

The company profile lists revenue (TTM) near $9M, net income (TTM) near $-9.77B, EPS (TTM) near $-48.32 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Wellgistics Health Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Tampa, Florida, US, 2.9M shares outstanding, ISIN US9495031067 when available from company profile and filing metadata.

Wellgistics Health Inc (MEDS) Stock Analysis & Quote

Please enable JavaScript to continue using this application.

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. The company is headquartered in Tampa, Florida. The company went IPO on 2025-02-21. The company focuses on specialty medications and a community-based model offering home delivery services to patients. The company is focused on improving the lives of patients while delivering solutions for pharmacies, providers, pharmaceutical manufacturers, and payors. Its technology platform, DelivMeds, serves as a pharmacy hub and allows for clinical services to be connected to the Company’s health pharmacy operations. This platform will allow for an end-to-end mobile application solution whereby patients can digitize their prescription journey. The solution helps to preserve patient autonomy, improve prescription price transparency, and provide additional concierge services. Its products include Kyzatrex and Semaglutide and Tirzepatide.

Employees

Website

wellgisticshealth.com/

IPO

2025-02-21

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)